Clinical Trials Logo

Neuropathy, Diabetic clinical trials

View clinical trials related to Neuropathy, Diabetic.

Filter by:

NCT ID: NCT03989063 Recruiting - Diabetes Mellitus Clinical Trials

Motor Learning in Individuals With Lower Limb Loss and Chronic Diabetes

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Inadequate rehabilitation training after amputation can result in poor patient outcomes, injuries, and wasted healthcare resources. This is a serious public health problem due to an aging population and rising prevalence of diabetes (main cause of amputation in the U.S.). In this study, the investigators will examine the effects of external vs. internal attentional focus instruction on learning of a balance task in individuals with existing amputation and those at risk of amputation (older adults with diabetes). With the proposed research, the investigators aim to expand the understanding of motor learning in individuals with and at risk of lower limb loss to provide knowledge that will lead to more effective and efficient rehabilitation.

NCT ID: NCT03847129 Completed - Diabetes Mellitus Clinical Trials

Assessments and Interventions for Hand Neuropathy in DM

Start date: August 20, 2015
Phase: N/A
Study type: Interventional

This study is to investigate the effects of task-based biofeedback training compared with home-based programs on sensorimotor function and quality of life for diabetic patients with neuropathic hands. The investigators hypothesize that the task-based biofeedback training might have significant effectiveness for restoration of sensory function, precision pinch performance, hand dexterity and life quality for patients with diabetic neuropathy.

NCT ID: NCT03777956 Terminated - Neuropathic Pain Clinical Trials

The Effect of Lacosamide in Peripheral Neuropathic Pain

Start date: January 15, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to compare the change in pain intensity during treatment with a sodium-channel blocker (lacosamide) in patients with peripheral neuropathic pain with and without the irritable nociceptor phenotype.

NCT ID: NCT03700580 Completed - Diabetic Foot Clinical Trials

Clinical Trial Using the Proteolytic Fraction P1G10 From V. Cundinamarcensis to Heal Diabetic Foot Ulcer

P1G10
Start date: August 15, 2012
Phase: Phase 2
Study type: Interventional

The aim of the study was to investigate the role of the proteolytic fraction from Vasconcellea cundinamarcensis, designated as P1G10, on healing of chronic foot ulcers in neuropathic patients diagnosed with diabetes type 2. Fifty patients were enrolled in a prospective, randomized, double-blind trial, to verify the efficacy and safety of a topical dressing containing 0.1% P1G10, versus a Hydrogel (positive control) protocol currently applied at the Health Center to treat this condition. Upon completion of the intervention, the outcome evaluated the number of patients attaining full epithelization (100%), or at least 80% healing in both arms (P1G10 versus Hydrogel). Statistical analysis compared the endpoint data on each group to assess the significance of differences.

NCT ID: NCT03495089 Completed - Clinical trials for Diabetes Mellitus, Type 2

DECODING Study (Dermal Electrochemical Conductance in Diabetic Neuropathy)

DECODING
Start date: May 2015
Phase: N/A
Study type: Interventional

Diabetes mellitus is the leading cause of polyneuropathy in the Western world. Diabetic neuropathy is a frequent complication of diabetes and may have great clinical transcendence due to pain and possible ulceration of the lower extremities. It is also a relevant cause of morbidity and mortality in patients with diabetes. Although the cause of polyneuropathy in patients with diabetes is only partially known, it has been associated with chronic hyperglycaemia suggesting the possible aetiopathogenic implication of advanced glycosylation end-products. The strategy of choice in the medical management of diabetic neuropathy is early detection since glycaemic control and the use of certain drugs may prevent or slow the development of this disease. Diabetic neuropathy most often presents with a dysfunction of unmyelinated C-fibers, manifested as an alteration of the sweat reflex of the eccrine glands. This dysfunction can now be demonstrated using a newly developed technology which measures dermal electrochemical conductivity. This noninvasive test is easy and cost-effective. The aim of the present study is to evaluate the feasibility and effectiveness of dermal electrochemical conductance measurement (quantitative expression of the sudomotor reflex) as a screening test for the diagnosis of diabetic neuropathy in patients in primary care.

NCT ID: NCT03195868 Completed - Neuropathy Clinical Trials

Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy

Start date: September 30, 2019
Phase: N/A
Study type: Interventional

This study seeks to determine if photobiomodulation (PBM, or low level laser light) affects the growth and distribution of nerves int he skin. Our previous study demonstrated that the treatment we use here was effective at reducing the symptoms of neuropathy (as measured by the modified total neuropathy score) in patients who had been treated with chemotherapy. The current effort is designed to repeat this confirm this observation using a more extensive battery of survey as well as to begin to elucidate the mechanism through which photobiomodulaiton produces the effect. WE will also be attempting to determine if diabetic patients differ in terms of response from chemotherapy patients

NCT ID: NCT00643760 Completed - Clinical trials for Neuropathy, Diabetic

A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with diabetic peripheral neuropathy(DPN)

NCT ID: NCT00422955 Completed - Clinical trials for Neuropathy, Diabetic

Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.

Start date: November 2003
Phase: Phase 3
Study type: Interventional

Fluid management study in patients with type 2 diabetes and autonomic neuropathy.